Object's details: Experience of Magnesium and L-Carnitine Combine Use for Correction of Structural and Functional Heart Changes in Type 2 Diabetic Patients with End-Stage Kidney Disease

Provider:Akademicka Platforma Czasopism

Description

Title:
Experience of Magnesium and L-Carnitine Combine Use for Correction of Structural and Functional Heart Changes in Type 2 Diabetic Patients with End-Stage Kidney Disease
Creator:
Susla, Oleksandr;
Litovkina, Zoriana;
Yakubyshyna, Inna
Description:
Introduction and purpose: It is important today to develop new pathogenetic strategies to reduce cardiovascular risk in type 2 diabetic patients with end-stage kidney disease (ESKD). The purpose of the study was to evaluate the efficacy of combine use of magnesium aspartate and L-Carnitine on character of heart changes in dynamics of complex treatment of the patients with diabetic kidney disease (DKD) undergoing hemodialysis (HD). Material and methods: 42 type 2 diabetic ESKD patients were included in this prospective cohort study (male/female, 26/16; age, 59.5±0.7 years; HD duration, 31.2±4.6 months; diabetes mellitus duration, 174,6±7,8 months). The patients were divided into two groups: the 1st (main) group (n=22) was treated by combination of magnesium aspartate (0.5 g/day orally) by three 2-months’ courses/year and L-carnitine (1 g/day parenterally after each HD session) throughout the year; the 2nd (comparison) group (n=20) was only on the basic therapy. The observation time was 12 months. A complete echocardiography and ultrasound scanning of common carotid arteries (CCA) were performed. Results: During follow up period we found the reduction of the left atrium (p=0.008) and left ventricle (LV) diameters (p=0.004), decrease of LV mass index for 17,1% (p=0.005) and prevalence of pseudonormal and restrictive types of LV diastolic dysfunction for 53.3% (p=0.026), increase of the LV ejection fraction for 5.4% (p=0.004), and decrease the mean pulmonary artery pressure for 13% (p=0.009) in the main group. The annual incidence of both mitral and aortic valve calcification in the 2nd group was 10%, in the 1st group – 0%. After 12 months of treatment, increase of the CCA intima-media thickness (p=0.23) was recorded in the comparison group only. Conclusions: The combine use of magnesium and L-carnitine as part of a 12-month complex therapy provides an effective reduction ofLV hypertrophy, improves its systolic and diastolic function, reduces pulmonary hypertension, and prevents the progression of cardiac valve calcification and atherosclerotic damage.
Object availability:
free access
Rights:
Prawa autorskie (c) 2020 © The Author (s)
Date:
2020.12.28
Type:
info:eu-repo/semantics/article;
info:eu-repo/semantics/publishedVersion
Language:
English
Source:
Journal of Education, Health and Sport; Vol. 10 No. 12 (2020); 286-303;
Journal of Education, Health and Sport; Tom 10 Nr 12 (2020); 286-303;
2391-8306
Format:
application/pdf
Publisher:
Nicolaus Copernicus University, Toruń, Poland
Relation: https://apcz.umk.pl/JEHS/article/view/JEHS.2020.10.12.029/28356
Subject:
hemodialysis;
diabetic kidney disease;
heart remodeling;
calcification of mitral and aortic valve;
carotid intima-media thickness;
progression;
magnesium aspartate;
L-carnitine
Identifier: https://apcz.umk.pl/JEHS/article/view/JEHS.2020.10.12.029
Data provider:
Akademicka Platforma Czasopism

Similar objects

Experience of Magnesium and L-Carnitine Combine Use for Correction of Structural and Functional Heart Changes in Type 2 Diabetic Patients with End-Stage Kidney Disease

Creator:Susla, Oleksandr | Litovkina, Zoriana | Yakubyshyna, Inna

Date:2020.12.28

Type:text

SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review

Date:2024.12.08

Type:text

Finerenone as a therapeutic option for managing chronic kidney disease (CKD) linked to type 2 diabetes (T2D) and his other potential use. A summary of current research findings

Date:2025.07.11

Type:text

Psoriasiform lesions as a side effect of SGLT-2 therapy

Creator:Gałązka, Jakub Krzysztof | Domagalski, Łukasz | Homa, Piotr | Hoffman, Zofia

Date:2023.01.17

Type:text

Diabetic kidney disease: what we know so far - literature review

Date:2024.08.16

Type:text

L-carnitine supplementation in female infertility – is it working?

Date:2023.05.31

Type:text

Cardiovascular Features of Chronic Inflammation and Endothelial Dysfunction in Patients with Diabetic Nephropathy on Programmed Hemodialysis

Creator:Litovkina, Zoriana І. | Susla, Oleksandr B.

Date:2020.10.30

Type:text

The role of the gut microbiota in the pathogenesis and therapy of type 2 diabetes mellitus

Date:2024.01.22

Type:text

Federacja Bibliotek Cyfrowych

Object's details: Experience of Magnesium and L-Carnitine Combine Use for Correction of Structural and Functional Heart Changes in Type 2 Diabetic Patients with End-Stage Kidney Disease

Description

Similar objects